Trauma & Toxicology drugs

7 results

  • auvi-q

    (epinephrine)
    kaleo, Inc
    AUVI-Q® is indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis due to insect stings, food, medications, and other allergens. It is intended for immediate self-administration in individuals at risk for anaphylaxis and is not a substitute for medical care.

  • baqsimi

    (glucagon)
    Eli Lilly and Company
    BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes aged 4 years and older.

  • brilinta

    (Ticagrelor)
    AstraZeneca Pharmaceuticals LP
    BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also reduces the risk of first myocardial infarction or stroke in high-risk coronary artery disease patients and ischemic stroke/TIA patients.

  • panhematin

    (hemin)
    Recordati Rare Diseases, Inc.
    PANHEMATIN is indicated for alleviating recurrent acute intermittent porphyria attacks linked to the menstrual cycle in women when carbohydrate therapy is insufficient. It aims to prevent severe attacks, but is not effective for repairing existing neuronal damage. Prior carbohydrate loading is recommended before administration.

  • rayos

    (prednisone)
    Horizon Therapeutics USA, Inc.
    RAYOS is indicated for severe allergic conditions, various dermatologic and endocrine diseases, gastrointestinal disorders (like Crohn's and ulcerative colitis), hematologic issues, neoplasms, nervous system conditions (such as multiple sclerosis), certain ophthalmic diseases, organ transplant rejection, pulmonary disorders, renal conditions, rheumatologic ailments, and specific infectious diseases.

  • vistogard

    (uridine triacetate)
    Wellstat Therapeutics Corporation
    VISTOGARD® is indicated for the emergency treatment of adults and pediatric patients after a fluorouracil or capecitabine overdose, or those experiencing severe toxicity or adverse reactions within 96 hours post-administration. It is not recommended for non-emergency use, as it may reduce the efficacy of these drugs.

  • voraxaze

    (glucarpidase)
    BTG International Inc.
    VORAXAZE is indicated for reducing toxic plasma methotrexate levels in adults and pediatric patients with delayed clearance due to impaired renal function. It should not be used in patients with expected clearance, as it may lead to inadequate methotrexate exposure.